The antitumor activity of oxaliplatin in a nude mouse xenograft tumor model also indicated tumor growth to be substantially suppressed in wild-type p53-expressing CRC cells, whereas little effect of oxaliplatin was observed in p53-deficient cells. This evidence concerns the gene TP53 and colorectal carcinoma.